Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00145847 · ClinicalTrials.gov registry record · Phase 4
Naltrexone Treatment of Alcohol Abuse in Schizophrenia
A Phase 4 study of Schizophrenia and Alcoholism, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
- 4
- Study locations
NCT00145847: Completed Phase 4 study of Schizophrenia and Alcoholism, sponsored by State University of New York - Upstate Medical University.
NCT00145847 is a Phase 4 study of Schizophrenia and Alcoholism that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 90 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (59% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00145847, a Phase 4 study of Schizophrenia and Alcoholism, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary purpose of this study is to determine whether naltrexone is effective in the treatment of alcohol dependence and abuse in patients with schizophrenia and schizoaffective disorder. Hypotheses are as follows: hypothesis 1: Naltrexone will be more effective than placebo in reducing alcohol use. hypothesis 2: Patients responding to naltrexone by reducing alcohol use will also show reductions in severity of psychiatric symptoms and utilization of inpatient and emergency psychiatric services. hypothesis 3: Severity of psychiatric symptoms and amount of service utilization will correlate positively with alcohol use.
Conditions Studied
Interventions
- DRUG Naltrexone or Placebo
Study Locations (4)
New York
- St. Joseph's Mental Health Services - Syracuse
- Hutchings Psychiatric Center - Syracuse
- SUNY Upstate Medical University - Syracuse
- Veterans Administration Healthcare Center - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2003-04 |
| Est. Completion | 2008-05 |
| Phase | Phase 4 |
What the finished NCT00145847 record still lists
NCT00145847 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (59% lower).
The record links to 5 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Naltrexone or Placebo is the first listed.
NCT00145847 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00145847 about?
NCT00145847 is a clinical study titled "Naltrexone Treatment of Alcohol Abuse in Schizophrenia". The primary purpose of this study is to determine whether naltrexone is effective in the treatment of alcohol dependence and abuse in patients with schizophrenia and schizoaffective disorder. Hypotheses are as follows: hypothesis 1: Naltrexone will be more effective than placebo in reducing alcohol...
What is the current status of trial NCT00145847?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2003-04. Estimated completion is 2008-05.
What conditions does trial NCT00145847 study?
This clinical trial studies the following conditions: Schizophrenia, Alcoholism, Alcohol Abuse, Mental Disorders, Alcohol-Related Disorders.
What interventions are being tested in trial NCT00145847?
The interventions under investigation include: Naltrexone or Placebo (DRUG).
Who is sponsoring clinical trial NCT00145847?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00145847 being conducted?
This trial has 4 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00145847's enrollment target sits among peer trials
90 151st of 315 higher than 164 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia